Pharmaceutical composition suitable for intestinal administration

• US 4,639,435 A
• Filed: 06/27/1984
• Issued: 01/27/1987
• Est. Priority Date: 06/29/1983
• Status: Expired due to Fees

• Current Assignee: KOWA Company Limited
• Original Assignee: KOWA Company Limited
• Inventors: Fujii, Setsuro, Nagakura, Masahiko, Yokoo, Nobuo, Ikegaya, Kouji, Yokoyama, Touru
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US06/625,231
• Time in Patent Office: 944 Days
• Field of Search: 260/112.5 R, 514/11, 514/10, 514/12, 514/808
• US Class Current: 424/94.64
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 38/005 Enzyme inhibitors protease inhibitors A61K38/55
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical composition is disclosed which comprises a physiologically active substance possessing peptide bonds in its structure and being inactivable by digestive enzymes, the active substance being other than insulin, and a synthetic chymotrypsin inhibitor. The composition is particularly suitable for intestinal absorption of the active substance.

Claims

1. A pharmaceutical composition suitable for intestinal absorption, comprising (i) a physiologically active substance which is at least one member selected from the group consisting of kallikrein and calcitonin, and (ii) 1-isopropyl-4-[4-(1,2,3,4-tetrahydronaphthoyloxy)-benzoyl] piperazine methanesulfonate.

3. The pharmaceutical composition of claim 1, wherein the said physiologically active substance is calcitonin.

2. The pharmaceutical composition 1, wherein the said physiologically active substance is kallikrein.